Literature DB >> 16417599

Botulinum toxin therapy of writer's cramp.

C P Das1, D Dressler, M Hallett.   

Abstract

The pathophysiology and management of writer's cramp is one of the most challenging amongst the various forms of focal dystonias. Frequently, the dystonic postures are confounded by compensatory muscle activity. Correct identification of target muscles for botulinum toxin (BT) injections determines the treatment success. The dosages of different preparations vary, with 1 unit of Botox roughly equalling 3.5 units of Dysport. Electromyographic guided injections yield better results and may also decrease the amount of toxin required. Weakness of target muscles interfering with other non-writing activities is a frequently encountered adverse effect. Studies have shown that BT is a safe long-term therapy option.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417599     DOI: 10.1111/j.1468-1331.2006.01446.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  11 in total

Review 1.  Neuroimaging characteristics of patients with focal hand dystonia.

Authors:  Leighton B N Hinkley; Rebecca L Webster; Nancy N Byl; Srikantan S Nagarajan
Journal:  J Hand Ther       Date:  2009-02-12       Impact factor: 1.950

2.  Therapeutic immobilisation for small guitar player's dystonia: a case report.

Authors:  Flavia Waissman; João Santos Pereira; Osvaldo J M Nascimento
Journal:  BMJ Case Rep       Date:  2009-05-25

3.  Botulinum toxin and occupational therapy for Writer's cramp.

Authors:  Jung E Park; Ejaz A Shamim; Pattamon Panyakaew; Pawan Mathew; Camilo Toro; Jonathan Sackett; Barbara Karp; Codrin Lungu; Katharine Alter; Tianxia Wu; Omar F Ahmad; Monica Villegas; Sungyoung Auh; Mark Hallett
Journal:  Toxicon       Date:  2019-07-24       Impact factor: 3.033

4.  Motor re-training does not need to be task specific to improve writer's cramp.

Authors:  Kirsten E Zeuner; Martin Peller; Arne Knutzen; Mark Hallett; Günther Deuschl; Hartwig R Siebner
Journal:  Mov Disord       Date:  2008-12-15       Impact factor: 10.338

5.  Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.

Authors:  Kerstin Müller; Eilhard Mix; Fereshte Adib Saberi; Dirk Dressler; Reiner Benecke
Journal:  J Neural Transm (Vienna)       Date:  2009-04-08       Impact factor: 3.575

6.  Botulinum toxin in the management of dystonia.

Authors:  Omar D Cardona-Garcia; Donald S Higgins; Eric S Molho
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

7.  Therapeutic use of botulinum toxin in neurorehabilitation.

Authors:  Domenico Intiso
Journal:  J Toxicol       Date:  2011-09-14

Review 8.  Variability of Botulinum Toxins: Challenges and Opportunities for the Future.

Authors:  Christine Rasetti-Escargueil; Emmanuel Lemichez; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2018-09-13       Impact factor: 4.546

9.  Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment.

Authors:  André Lee; Jabreel Al-Sarea; Eckart Altenmüller
Journal:  Toxins (Basel)       Date:  2021-05-22       Impact factor: 4.546

10.  Neurologic uses of botulinum neurotoxin type A.

Authors:  John P Ney; Kevin R Joseph
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.